Interesting take on receptors… if receptors don’t fatigue, why is dose escalation typically required to maintain efficacy?
My thought is he’s 50-100% below a therapeutic dose of Reta. Reta has roughly 1/10th the glp exposure as sema. Getting to a therapeutic dose of Reta would give him the benefits of glucagon, with approximately appropriate glp exposure. Split dosing would reduce the peak exposure while maintaining the average exposure. Without getting the benefit of typically therapeutic levels of glucagon, why take Reta over Tirz?